Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beta-blocker withdrawal in HFpEF and chronotropic incompetence
NCT03871803Phase 4Completed
- Sponsor
- INCLIVA Biomedical Research Institute
- Start
- Oct 2018
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of carvedilol in heart failure with preserved ejection fraction (HFpEF) (2 arms), sponsored by INCLIVA Biomedical Research Institute. Primary endpoint: Peak Oxygen Consumption at 30 days. Started Oct 2018; status: completed.
02
Drugs
carvedilol
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT03871803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03871803.